Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) has issued an announcement.
Hangzhou Tigermed Consulting Co., Ltd. reported a decline in its financial performance for the first half of 2025, with revenue, gross profit, and net profit all decreasing compared to the same period in 2024. The company attributes these challenges to the volatile demand for R&D in the domestic biopharmaceutical industry, influenced by global macroeconomic cycles and shifts in client risk appetites. Despite these challenges, the company remains optimistic about future opportunities, as China’s biopharmaceutical industry continues to advance with a focus on high-quality, innovative R&D projects.
The most recent analyst rating on (HK:3347) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.
More about Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. operates in the biopharmaceutical industry, providing clinical research outsourcing services. The company focuses on supporting research and development (R&D) in the biopharmaceutical sector, which has seen significant growth in China, transitioning from a focus on generic drugs to innovative medicines.
Average Trading Volume: 4,878,203
Technical Sentiment Signal: Buy
Current Market Cap: HK$55.09B
Learn more about 3347 stock on TipRanks’ Stock Analysis page.